Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension

Abstract. Endothelin receptor antagonists (ERAs) have been shown to improve the prognosis of patients with pulmonary arterial hypertension (PAH). However, the effect of the oral dual ERA bosentan on peripheral endothelial dysfunction (PED), as assessed by flow-mediated vasodilation (FMD), in patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pulm Circ
Autors principals: Hirashiki, Akihiro, Adachi, Shiro, Nakano, Yoshihisa, Kamimura, Yoshihiro, Shimokata, Shigetake, Takeshita, Kyosuke, Murohara, Toyoaki, Kondo, Takahisa
Format: Artigo
Idioma:Inglês
Publicat: University of Chicago Press 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869920/
https://ncbi.nlm.nih.gov/pubmed/27252842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/685715
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars